48.30
-0.91(-1.85%)
Currency In USD
| Previous Close | 49.21 |
| Open | 49.63 |
| Day High | 49.77 |
| Day Low | 47.88 |
| 52-Week High | 51.19 |
| 52-Week Low | 18.53 |
| Volume | 1.81M |
| Average Volume | 1.62M |
| Market Cap | 3.09B |
| PE | -12.11 |
| EPS | -3.99 |
| Moving Average 50 Days | 32.37 |
| Moving Average 200 Days | 25.8 |
| Change | -0.91 |
If you invested $1000 in Vera Therapeutics, Inc. (VERA) since IPO date, it would be worth $4,200 as of December 17, 2025 at a share price of $48.3. Whereas If you bought $1000 worth of Vera Therapeutics, Inc. (VERA) shares 3 years ago, it would be worth $2,581.51 as of December 17, 2025 at a share price of $48.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
GlobeNewswire Inc.
Nov 26, 2025 9:05 PM GMT
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
GlobeNewswire Inc.
Nov 10, 2025 12:29 PM GMT
BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological dise
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
GlobeNewswire Inc.
Nov 07, 2025 11:27 PM GMT
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo